Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
PD0325901
Cat No.
CEI-0162
Description
As an non-ATP competitive inhibitor, PD0325901 can inhibit MEK with Ki around 1 nM.
CAS No.
391210-10-9
Molecular Weight
482.19
Purity
>99%
Storage
2 years at -20centigrade Powder
Targets
MEK
Molecular Formula
C16H14F3IN2O4
Chemical Name
(R)-N-(2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)benzamide
Solubility
DMSO 96 mg/mL Water
In vitro
As an non-ATP competitive inhibitor, PD0325901 can inhibit MEK with Ki around 1 nM. PD0325901 can inhibit the PTC cells with the RET/PTC1 rearrangement with GI50 of 11 nM and also inhibit PTC cells with a BRAF mutation with GI50 of 6.3 nM. PD0325901 markedly inhibited ERK phosphorylation and growth of both BRAF mutant and wild-type melanoma cell lines, with IC50 in the nanomolar range. PD0325901 can cause G(1)-phase cell cycle arrest and subsequent induction of apoptosis by modulating cell cycle (cyclin D1, c-Myc, and p27) and apoptosis (Bcl-2 and survivin) regulators.
In vivo
For SKMEL-28 and HCT116 tumors, tumor volumes were not significantly reduced at day 1 following PD0325901 (25 mg/kg) treatment. In SKMEL-28, tumor volume changed from 168.0 mm3 (pretreatment group) to 181.2 mm3 and 248.0 mm3 at days 1 and 10, respectively, following treatment with vehicle.Tumor shrinkage was observed after daily treatment with PD0325901 (25 mg/kg) to 135.8 and 43.2 mm3 (P = 0.05), at days 1 and 10, respectively. HCT116 tumor volumes showed a rapid increase in the vehicle-treated group from 106.670 mm3 (pretreatment group) to 136.7 mm3 and 542.3 mm3 at days 1 and 10, respectively.
Download
Download Datasheet